From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany)

Radon K, Bakuli A, Pütz P, Gleut RL, Guggenbuehl Noller JM, Olbrich L, Saathoff E, Garí M, Schälte Y, Frahnow T, Wölfel R, et al. (2021)
BMC Infectious Diseases 21(1): 925.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Radon, Katja; Bakuli, Abhishek; Pütz, PeterUniBi; Gleut, Ronan Le; Guggenbuehl Noller, Jessica Michelle; Olbrich, Laura; Saathoff, Elmar; Garí, Mercè; Schälte, Yannik; Frahnow, TuridUniBi ; Wölfel, Roman; Pritsch, Michael
Alle
Abstract / Bemerkung
BACKGROUND: In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021.; METHODS: The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N=2768) as well as leisure time activities (N=1263) were collected in summer 2020.; RESULTS: Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9-4.3%) as compared to 1.8% (95% CI 1.3-3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2020 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20-34years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences.; CONCLUSION: The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of SARS-CoV-2 sero-positive baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important. © 2021. The Author(s).
Erscheinungsjahr
2021
Zeitschriftentitel
BMC Infectious Diseases
Band
21
Ausgabe
1
Art.-Nr.
925
eISSN
1471-2334
Page URI
https://pub.uni-bielefeld.de/record/2956797

Zitieren

Radon K, Bakuli A, Pütz P, et al. From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany). BMC Infectious Diseases. 2021;21(1): 925.
Radon, K., Bakuli, A., Pütz, P., Gleut, R. L., Guggenbuehl Noller, J. M., Olbrich, L., Saathoff, E., et al. (2021). From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany). BMC Infectious Diseases, 21(1), 925. https://doi.org/10.1186/s12879-021-06589-4
Radon, Katja, Bakuli, Abhishek, Pütz, Peter, Gleut, Ronan Le, Guggenbuehl Noller, Jessica Michelle, Olbrich, Laura, Saathoff, Elmar, et al. 2021. “From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany)”. BMC Infectious Diseases 21 (1): 925.
Radon, K., Bakuli, A., Pütz, P., Gleut, R. L., Guggenbuehl Noller, J. M., Olbrich, L., Saathoff, E., Garí, M., Schälte, Y., Frahnow, T., et al. (2021). From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany). BMC Infectious Diseases 21:925.
Radon, K., et al., 2021. From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany). BMC Infectious Diseases, 21(1): 925.
K. Radon, et al., “From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany)”, BMC Infectious Diseases, vol. 21, 2021, : 925.
Radon, K., Bakuli, A., Pütz, P., Gleut, R.L., Guggenbuehl Noller, J.M., Olbrich, L., Saathoff, E., Garí, M., Schälte, Y., Frahnow, T., Wölfel, R., Pritsch, M., Rothe, C., Pletschette, M., Rubio-Acero, R., Beyerl, J., Metaxa, D., Forster, F., Thiel, V., Castelletti, N., Rieß, F., Diefenbach, M.N., Fröschl, G., Bruger, J., Winter, S., Frese, J., Puchinger, K., Brand, I., Kroidl, I., Wieser, A., Hoelscher, M., Hasenauer, J., Fuchs, C.: From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany). BMC Infectious Diseases. 21, : 925 (2021).
Radon, Katja, Bakuli, Abhishek, Pütz, Peter, Gleut, Ronan Le, Guggenbuehl Noller, Jessica Michelle, Olbrich, Laura, Saathoff, Elmar, Garí, Mercè, Schälte, Yannik, Frahnow, Turid, Wölfel, Roman, Pritsch, Michael, Rothe, Camilla, Pletschette, Michel, Rubio-Acero, Raquel, Beyerl, Jessica, Metaxa, Dafni, Forster, Felix, Thiel, Verena, Castelletti, Noemi, Rieß, Friedrich, Diefenbach, Maximilian N., Fröschl, Günter, Bruger, Jan, Winter, Simon, Frese, Jonathan, Puchinger, Kerstin, Brand, Isabel, Kroidl, Inge, Wieser, Andreas, Hoelscher, Michael, Hasenauer, Jan, and Fuchs, Christiane. “From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany)”. BMC Infectious Diseases 21.1 (2021): 925.

Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

References

Daten bereitgestellt von Europe PubMed Central.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 34493217
PubMed | Europe PMC

Preprint: 10.1101/2021.04.27.21256133

Suchen in

Google Scholar